NCT05848466 2026-03-30
Assessment of Safety, Tolerability and Pharmacokinetics With BAT8010 for Injection in Advanced Malignant Solid Tumors Patients
Bio-Thera Solutions
Phase 1 Completed
Clinical Trials
11 trialsNCT06248411 2026-03-18
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Kyowa Kirin Co., Ltd.
Phase 1 Recruiting
NCT06234397 2026-03-11
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Recruiting
NCT05957081 2025-12-30
MarkV-01
PharmAbcine
Phase 1 Recruiting
NCT06724016 2025-12-17
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Recruiting
NCT07260305 2025-12-03
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Kangabio AUSTRALIA LTD PTY
Phase 1 Recruiting
NCT06752681 2025-10-10
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 1 Recruiting
NCT06548217 2025-07-03
A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT05785754 2025-06-26
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
DynamiCure Biotechnology
Phase 1 Recruiting
NCT03155061 2025-06-05
Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors
Ono Pharmaceutical Co. Ltd
Phase 1 Active not recruiting
NCT05598151 2025-04-30
Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
Hanmi Pharmaceutical Company Limited
Phase 1 Recruiting